Hanmi and Janssen sign agreement to develop HM12525A
11 November 2015 | By Victoria White
HM12525A is a novel biologic GLP-1/Glucagon dual receptor agonist to treat diabetes and obesity...
List view / Grid view
News
FDA approves Cotellic plus Zelboraf in advanced melanoma
11 November 2015 | By Victoria White
The approval is for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma...
Anifrolumab met primary and secondary endpoints in lupus trial
10 November 2015 | By Victoria White
Anifrolumab is a new monoclonal antibody against the type I interferon (IFN) receptor that inhibits the activity of all type I IFNs, which play a central role in lupus...
Lilly’s ixekizumab demonstrates efficacy in psoriatic arthritis
10 November 2015 | By Victoria White
Psoriatic arthritis patients treated with ixekizumab for 24 weeks achieved significant improvements in signs and symptoms of their disease compared to placebo...
Investigational Enbrel biosimilar CHS-0214 meets primary endpoints
10 November 2015 | By Victoria White
CHS-0214 met its primary endpoints in a Phase 3 study in patients with moderate-to-severe chronic plaque psoriasis...
SMC accepts Keytruda as a treatment option for advanced melanoma
10 November 2015 | By Victoria White
The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)...
Study demonstrates clinical equivalence of ABP 501 with adalimumab
10 November 2015 | By Victoria White
ABP 501 is being developed as a biosimilar candidate to adalimumab, an anti-TNF-α monoclonal antibody, which is approved in many countries for the treatment of inflammatory diseases...
Astellas to acquire Ocata Therapeutics for $379 million
10 November 2015 | By Victoria White
Acquiring Ocata will enable Astellas to establish a presence in ophthalmology and a leading position in cell therapy...
Baricitinib demonstrates superiority to adalimumab in rheumatoid arthritis
Baricitinib demonstrated superiority over adalimumab (Humira) after 12 weeks based on several critical measures of rheumatoid arthritis disease activity...
FDA approves Gilead’s Genvoya for the treatment of HIV
6 November 2015 | By Victoria White
Genvoya contains a new form of tenofovir that has not been previously approved...
Sanofi and Lexicon collaborate on sotagliflozin
6 November 2015 | By Victoria White
Sotagliflozin is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 which could be a potential treatment option for people with diabetes...
AstraZeneca to acquire ZS Pharma for $2.7 billion
6 November 2015 | By Victoria White
The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia...
EMA validates type II variation application for Opdivo in RCC
6 November 2015 | By Victoria White
Validation of the application confirms the submission is complete and begins the EMA’s centralised review process...
INO-3112 shows robust responses in head and neck cancer
6 November 2015 | By Victoria White
Immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18...
UCART19 used to treat ‘incurable’ leukaemia
6 November 2015 | By Victoria White
A team at Great Ormond Street Hospital has used UCART 19 cells to treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia with positive results...
